| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/17/2000 | CA2292246A1 New hydrazide derivatives, the procedure for preparing them and the pharmaceutical formulations that contain them |
| 06/15/2000 | WO2000034495A2 A method of genetically modifying very primitive quiescent human hematopoietic stem cells |
| 06/15/2000 | WO2000034485A2 Beta-1,3-galactosyltransferase homologs |
| 06/15/2000 | WO2000034475A2 Grnf4, a gdnf-related neurotrophic factor |
| 06/15/2000 | WO2000034474A2 Growth factor homolog zvegf3 |
| 06/15/2000 | WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders |
| 06/15/2000 | WO2000034451A1 Treatment of pompe's disease |
| 06/15/2000 | WO2000034334A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 06/15/2000 | WO2000034332A1 Glp-1 analogues |
| 06/15/2000 | WO2000034331A2 Analogues of glp-1 |
| 06/15/2000 | WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 06/15/2000 | WO2000034279A1 1,4-diazabicyclo[3.2.2]nonane derivatives, their preparation and therapeutic application |
| 06/15/2000 | WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 06/15/2000 | WO2000034241A1 N-substituted 2-cyanopyrrolidines |
| 06/15/2000 | WO2000034228A1 Ion channel modulating agents |
| 06/15/2000 | WO2000033877A1 Anhydrous topical skin preparations |
| 06/15/2000 | WO2000033876A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors |
| 06/15/2000 | WO2000033866A1 Pharmaceutical compositions containing insulin |
| 06/15/2000 | WO2000033865A1 Methods of inhibiting ectopic calcification |
| 06/15/2000 | WO2000033850A1 Remedies for hyperammonemia |
| 06/15/2000 | WO2000033844A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| 06/15/2000 | WO2000033843A1 Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases |
| 06/15/2000 | WO2000033837A2 Myt1 kinase inhibitors |
| 06/15/2000 | WO2000033834A1 Use of isatin derivatives as ion channel activating agents |
| 06/15/2000 | WO2000033828A1 Agent for lowering endothelin levels |
| 06/15/2000 | WO2000033817A1 Phospholipid compositions |
| 06/15/2000 | WO2000033813A1 Administration of neurotrophic agents to the central nervous system |
| 06/15/2000 | WO2000033667A2 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants |
| 06/15/2000 | WO1999045016A3 Novel prodrugs for phosphorus-containing compounds |
| 06/15/2000 | DE19958246A1 Isochinuclidinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende therapeutische Mittel gegen Hypercholesterinämie Isochinuclidinderivate, processes for their preparation containing these compounds and therapeutic agents for hypercholesterolemia |
| 06/15/2000 | DE19857009A1 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren Preparation with improved therapeutic index containing nucleotide synthesis |
| 06/15/2000 | CA2778047A1 Analogues of glp-1 |
| 06/15/2000 | CA2768016A1 Glp-1 analogues |
| 06/15/2000 | CA2354644A1 Muc-1 antagonists and methods of treating immune disorders |
| 06/15/2000 | CA2354266A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors |
| 06/15/2000 | CA2354189A1 Methods of inhibiting ectopic calcification |
| 06/15/2000 | CA2354040A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| 06/15/2000 | CA2354026A1 Beta-1,3-galactosyltransferase homologs |
| 06/15/2000 | CA2353522A1 Treatment of pompe's disease |
| 06/15/2000 | CA2352178A1 Phospholipid compositions |
| 06/15/2000 | CA2349616A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 06/14/2000 | EP1007691A1 Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
| 06/14/2000 | EP1007681A1 Method of increasing the iron content of plant cells |
| 06/14/2000 | EP1007648A1 Anti-obesity proteins |
| 06/14/2000 | EP1007639A1 GLUCOSE RESPONSIVE $g(b)-CELL LINE |
| 06/14/2000 | EP1007566A2 Therapeutic use of the smr1 protein and active derivatives thereof |
| 06/14/2000 | EP1007565A2 Transgenic animals with disrupted npy y1 receptor genes |
| 06/14/2000 | EP1007563A1 Hm74a receptor |
| 06/14/2000 | EP1007552A2 Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
| 06/14/2000 | EP1007539A1 Secreted proteins and polynucleotides encoding them |
| 06/14/2000 | EP1007514A1 Heterocyclic ketones as npy y5 antagonists |
| 06/14/2000 | EP1007512A1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors |
| 06/14/2000 | EP1007096A1 Arginine silicate inositol complex and use thereof |
| 06/14/2000 | EP1007093A1 Methods for treating disorders by using interleukin-9 and its antagonists |
| 06/14/2000 | EP1007090A1 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| 06/14/2000 | EP1007085A1 Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity |
| 06/14/2000 | EP1007068A1 Process for preparing synthetic soil-extract materials and medicaments based thereon |
| 06/14/2000 | EP1007043A1 Method for treatment of cns-involved lysosomal storage diseases |
| 06/14/2000 | EP1007042A1 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
| 06/14/2000 | EP1007039A1 Novel heterocyclic analogs of diphenylethylene compounds |
| 06/14/2000 | EP1007024A1 Delayed-release dosage forms of sertraline |
| 06/14/2000 | EP1007007A1 Ascorbic acid-based formulation with improved colour stability |
| 06/14/2000 | EP1006817A1 A food supplement composition based on dehydrated crab meat |
| 06/14/2000 | CN1256630A Parvitamin A correlation molecule for treating non-insulin dependent diabetes mellitus (NIDDM) |
| 06/14/2000 | CN1256629A Therapeutic compositions |
| 06/14/2000 | CN1256277A Phytostrin and/or phytosteroidal alkanol derivative |
| 06/14/2000 | CN1256252A Multielement mineral water and its preparation method and application |
| 06/14/2000 | CN1256140A Preparation of active material and Chinese medicine preparation for resisting diabetes and its complication |
| 06/14/2000 | CN1053438C Benzodiazepin-2-one derivatives, process for their prepn. and pharmaceutical composition containing them |
| 06/14/2000 | CN1053345C Adipsa soft extract and its prep. |
| 06/14/2000 | CN1053342C Prepn. process of thrombus dissolving agent for snake venom |
| 06/13/2000 | US6075151 Inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related hyperlipidemia, cardiovascular disorders |
| 06/13/2000 | US6075054 Antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment as well as for the treatment of angina pectoris |
| 06/13/2000 | US6075034 Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives |
| 06/13/2000 | US6075031 Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders |
| 06/13/2000 | US6074875 Materials and methods relating to the regulation of polypeptide production in cells |
| 06/13/2000 | US6074864 Spodoptera insect cell transformed by a vector coding a cerebroside enzyme for treating gaucher's disease |
| 06/13/2000 | US6074842 Amino acid and nucleotide sequences of human protein useful as markers to distinguish adipocytes from non-adipocyte, pathophysiologically lipid-laden cells; for probes and antibodies |
| 06/13/2000 | US6074670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
| 06/13/2000 | CA2030732C Thiophene derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 06/08/2000 | WO2000033068A1 Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| 06/08/2000 | WO2000033065A1 In vivo biosensor apparatus and method of use |
| 06/08/2000 | WO2000032634A1 Humanized antibodies to gamma-interferon |
| 06/08/2000 | WO2000032624A2 Uncoupling protein 5 - ucp5 |
| 06/08/2000 | WO2000032620A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 06/08/2000 | WO2000032600A1 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 06/08/2000 | WO2000032593A1 Method of producing paroxetine hydrochloride |
| 06/08/2000 | WO2000032589A1 Eletriptan hydrobromide monohydrate |
| 06/08/2000 | WO2000032582A1 Benzamide derivatives and their use as apob-100 secretion inhibitors |
| 06/08/2000 | WO2000032579A1 Substituted benzimidazoles and their use as parp inhibitors |
| 06/08/2000 | WO2000032575A1 β-ALANINE DERIVATIVES AS α4 INTEGRIN INHIBITORS |
| 06/08/2000 | WO2000032556A1 Derivatives of (-)-venlafaxine and methods of preparing and using the same |
| 06/08/2000 | WO2000032218A1 Controlled release formulation comprising gnrh-ii |
| 06/08/2000 | WO2000032215A1 PGC-1, A NOVEL BROWN FAT PPARη COACTIVATOR |
| 06/08/2000 | WO2000032198A1 Use of selected modulators of p2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischemia and ischemia-reperfusion |
| 06/08/2000 | WO2000032191A1 New pharmaceutical composition and the process for its preparation |
| 06/08/2000 | WO2000032189A1 Celecoxib compositions |
| 06/08/2000 | WO2000032180A2 Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids |
| 06/08/2000 | WO2000032178A2 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 06/08/2000 | WO2000032175A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |